Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

Abstract

This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery. The potential synergy between these three drugs needs to be confirmed, and is currently being investigated in a randomized phase II trial.

• Authors: Nicolas Williet, Olivier Dubreuil, Tarek Boussaha, Isabelle Trouilloud, Bruno Landi, Martin Housset, Muriel Botti, Philippe Rougier, Jacques Belghiti, Julien Taieb
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 17 Issue 17 Pg. 2255-8 (May 07 2011) ISSN: 2219-2840 [Electronic] United States
• PMID: 21633538 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzenesulfonates
• Organoplatinum Compounds
• Phenylurea Compounds
• Pyridines
• Oxaliplatin
• Deoxycytidine
• Niacinamide
• Sorafenib
• Gemcitabine

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Benzenesulfonates (administration & dosage, therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, pathology)
• Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
• Humans
• Liver Neoplasms (drug therapy, pathology)
• Male
• Middle Aged
• Neoadjuvant Therapy
• Niacinamide (analogs & derivatives)
• Organoplatinum Compounds (administration & dosage, therapeutic use)
• Oxaliplatin
• Phenylurea Compounds
• Pyridines (administration & dosage, therapeutic use)
• Sorafenib
• Gemcitabine